课题基金 / 基金详情

Anti-Apoptotic Mechanisms in BCR/ABL Leukemogenesis

Anti-Apoptotic Mechanisms in BCR/ABL Leukemogenesis
BCR/ABL 白血病发生中的抗凋亡机制
批准号:
6478162
负责人:
BRUNO CALABRETTA
金额:
$7.67万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
已结题
起止时间:
2001-06-01 至 2003-05-31

项目摘要

项目成果

BRUNO CALABRETTA的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The ability of BCR/ABL oncoproteins to induce leukemic transformation of hematopoietic cells depends on their tyrosine kinase activity, which is essential for the recruitment and the activation of multiple pathways (i.e., MAPkinase, Jun Kinase, PI-3k) that transduce oncogenic signals. Some of these pathways are also required for the anti-apoptotic effect of BCR/ABL. The objective of this proposal is t to delineate mechanisms involved in the survival-promoting effect of BCR/ABL and to assess the contribution of anti-apoptotic pathways for the leukmogenic potential of BCR/ABL. To this purpose, we will investigate mechanisms whereby three anti-apoptotic pathways regulated by BCR/ABL (Akt and STAT5 activation, mitochondrial targeting of Raf-1) promote cell survival and contribute to leukemogenesis. These studies should lead to a better understanding of the role of anti-apoptotic mechanisms in BCR/ABL leukemogenesis and the potential development of anti-leukemia therapies interfering with BCR/ABL-regulated survival signals.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A novel strategy for transcriptional reprogramming of lymphoid leukemia cells
  • 批准号:
    10392174
  • 项目类别:
  • 资助金额:
    $54.0万
  • 财政年份:
    2022
  • 负责人:
    BRUNO CALABRETTA
  • 依托单位:
A novel strategy for transcriptional reprogramming of lymphoid leukemia cells
  • 批准号:
    10543999
  • 项目类别:
  • 资助金额:
    $52.92万
  • 财政年份:
    2022
  • 负责人:
    BRUNO CALABRETTA
  • 依托单位:
Targeting CDK6 expression/activity in Ph+ and Ph1-like acute lymphoblastic leukemia (ALL)
  • 批准号:
    10437005
  • 项目类别:
  • 资助金额:
    $61.87万
  • 财政年份:
    2021
  • 负责人:
    BRUNO CALABRETTA
  • 依托单位:
Targeting CDK6 expression/activity in Ph+ and Ph1-like acute lymphoblastic leukemia (ALL)
  • 批准号:
    10317798
  • 项目类别:
  • 资助金额:
    $64.53万
  • 财政年份:
    2021
  • 负责人:
    BRUNO CALABRETTA
  • 依托单位:
国内基金
海外基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
  • 批准号:
    LBY21H010001
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2020
  • 负责人:
    郑绪阳
  • 依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
  • 批准号:
    81703335
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    20.0万元
  • 批准年份:
    2017
  • 负责人:
    卫高菲
  • 依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
  • 批准号:
    81670594
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2016
  • 负责人:
    陈昊
  • 依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
  • 批准号:
    81470791
  • 项目类别:
    面上项目
  • 资助金额:
    73.0万元
  • 批准年份:
    2014
  • 负责人:
    董家鸿
  • 依托单位: